Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Long-term Safety Study of Abiraterone Acetate
2011-005243-28Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started Feb 2012; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-005243-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005243-28.